公司资料
Veeva 股价、新闻与催化剂
- 股票代码:
- VEEV
- 交易所:
- NYSE
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
238.34 USD (-2.22%)
收盘价
最后更新: 2026年8月17日
29.9B USD
市值
股价为何变动
As of Aug 17, 2026, VEEV closed down 2.22% at $238.34. No new same-company headline was identified in the current news window.
公司概览
业务概览
Veeva Systems is a cloud software company built specifically for the life sciences industry. Its core products support commercial, clinical, regulatory, and data workflows for pharma and biotech customers, making it a key infrastructure name rather than a therapeutic developer.
所在地与行业分类
Headquartered in the United States and listed on NYSE, Veeva has a global footprint across life sciences companies. It sits in enterprise software and life sciences technology, not biotechnology proper.
商业模式特征
The business relies on recurring software subscriptions, customer retention, and cross-sell across commercial and development workflows. Investors tend to watch subscription growth, operating margin, product expansion, and the strength of the broader life sciences spending environment.
生物医药行业定位
Veeva is one of the most important software platforms in the biotech ecosystem. It is not a drug stock, but it matters because it helps power commercial and clinical operations across the sector.
未来催化剂
- Veeva’s catalysts are Vault CRM adoption, clinical-data-cloud traction, and continued penetration of regulated-life-science software. That readout matters because it decides whether the asset is ready for a larger and more expensive development step. If the data come in cleanly, the market tends to give the broader platform behind the program more credit.
近期新闻
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。